Top news
-
NovaMedica Launches Own Innovative Drug for the Treatment of Alzheimer’s Disease
19-April-2022
Russian pharmaceutical company NovaMedica (investment project of RUSNANO) has developed and registered an innovative combination of Donepezil and Memantine molecules, which are the basic therapy for dementia associated with Alzheimer's disease. The drug is registered under the name MIOREOL®. This is the first such combination in the Russian market and in the markets of the EAEU and Europe.
-
NovaMedica signed an agreement with Bayer on transfer of exclusive rights to its product
31-May-2021
Russian pharmaceutical company NovaMedica (part of the RUSNANO portfolio) and the corporation Bayer signed an agreement to provide Bayer with an exclusive license to commercialization of an innovative product developed by NovaMedica, including its manufacturing and promotion.
Media about us
-
RUSNANO has stopped the exit from a number of critically important assets for the country
10-June-2022
-
Technopolis Moscow has begun to produce a therapy for dementia
26-April-2022
-
NovaMedica launches an innovative Alzheimer’s disease therapy that it has developed
21-April-2022
-
Producers criticize excessive pharma market regulation in Russia
28-September-2021
Our news
-
27-September-2022
-
GXP News Contest takes competitors to R&D Center
25-August-2022
-
R&D Center NovaMedica Innotech becomes industrial partner of the Eurasian Academy of Good Practices
17-June-2022
Industry news
-
NEWS FDA approves first gene therapy for Haemophilia B
28-November-2022
-
Investments in the production of Russian substances for medicines may amount to 50 billion rubles
28-November-2022
-
Innovation in pharma manufacturing quality systems
24-November-2022